Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 ravulizumab study in adults with IgA nephropathy
CTR20241688Phase 3Active
- Sponsor
- Alexion Pharmaceuticals
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ravulizumab in IgA nephropathy (IgAN), sponsored by Alexion Pharmaceuticals. Started Oct 2024; status: active.
02
Drugs
ravulizumab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20241688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241688.